Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | SELL | P14151 | 1/20 | 0.38 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132200 | 0.93 | FFAR1 (0.48) | FFAR1KAT6APTGDR2C1SPTGER4 | |
| SCHEMBL5132030 | 0.92 | FFAR1 (0.50) | FFAR1KAT6APTGDR2C1SPTGER4 | |
| SCHEMBL5126365 | 0.87 | PTGDR2 (0.48) | KAT6APTGDR2TP53MDM2 | |
| SCHEMBL5122402 | 0.85 | MMP2 (0.44) | FFAR1KAT6APTGDR2C1SPTPN11 | |
| SCHEMBL5132510 | 0.85 | FFAR1 (0.44) | FFAR1PTPN11PTGER2 | |
| SCHEMBL5126655 | 0.85 | FFAR1 (0.49) | FFAR1KAT6APTGDR2PTPN11 | |
| SCHEMBL5132506 | 0.83 | KAT6A (0.42) | FFAR1KAT6APTGDR2PTPN11 | |
| SCHEMBL5126065 | 0.82 | FFAR1 (0.47) | FFAR1TP53MDM2PTGER4CTSA | |
| SCHEMBL5128717 | 0.82 | FFAR1 (0.44) | FFAR1KAT6APTPN11 | |
| SCHEMBL5132609 | 0.82 | SLC13A5 (0.41) | FFAR1KAT6APTGDR2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249137-A1 | PPAR active compounds | PLEXXIKON INC | 2008-10-09 | — | — | US | disclosed |
| US-20080249137-A1 | PPAR active compounds | PLEXXIKON INC | 2008-10-09 | — | — | US | disclosed |
| US-20080249137-A1 | PPAR active compounds | PLEXXIKON INC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249137-A1 | PPAR active compounds | PPARG, PPARA, PPARD | FFAR1 57/4885KAT6A 1424/4885PTGDR2 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.